isabelobrien, Author at European Medical Journal - Page 30 of 66

Building a high performance customer experience model

In the pharmaceutical industry, improving customer experience has become the goal, but it’s time to look at it in a new way.

world in hands

Novartis takes the top spot in 2024 Access to Medicine Index

Novartis has claimed the top spot in the 2024 Access to Medicine Index, displacing GSK after 16 consecutive years at the top.

Patrick Oliver, Alfasigma

Alfasigma’s Patrick Oliver on the company’s new chapter in the UK

Patrick Oliver, General Manager for the UK and Ireland at Alfasigma explores the company’s exciting entry into the UK market and the evolving healthcare landscape in the country.

Revisto raises $4m to streamline pharma compliance with AI

Revisto has raised $4m in seed funding to simplify the pharmaceutical industry’s marketing compliance processes using AI.

stamp of approval

FDA approves first gene therapy delivered directly to the brain

Discover how PTC Therapeutics’ treatment for a rare and fatal genetic disorder called aromatic l-amino acid decarboxylase (AADC) deficiency reached approval

5 minutes with… Roxana Redis, Charles River Laboratories

Roxana Redis, Associate Science Director of Advanced Modalities, Charles River Laboratories, talks about the exciting field of RNA.

Europe’s pharma R&D productivity grows, but falls behind US and China

Europe’s pharmaceutical research and development sector is in a tight spot as new data reveals that R&D spending isn’t keeping up with global competitors.

Coin stacks

AstraZeneca bets big on US, pledges to invest $3.5bn

Discover how AZ’s capital investment is set to expand its US research and manufacturing capabilities by the end of 2026.

Isabel O'Brien and Jade Williams

What should marketing and medical affairs invest in for Q4?

Join Jade and Isabel as they explore the critical trends that have shaped the industry in 2024 and what teams should leverage in Q4.

Red arrow tracking bar chart that is ascending in height

BMS, Gilead and Sanofi lead Q3 2024 market cap growth

The third quarter of 2024 brought a mix of gains and modest declines for the pharmaceutical industry’s top players, according to GlobalData.